High-risk HPV types in Tunisia. A pilot study reveals an unexpectedly high prevalence of types 58 and 82 and lack of HPV 18 among female prostitutes

Journal of Medical Virology

Volumn 78, Issue 7, 2006, Pages 950-953

  De Marco, Federico ^a   Houissa Kchouk, Fatma ^b   Khelifa, Ridha ^b   Marcante, Maria Luisa ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b HABIB THAMEUR HOSPITAL   (Tunisia)

Author keywords

Cervical cancer prevention and screening; Epidemiology; HPV epidemiological pockets; Mediterranean area; Multivalent HPV vaccine formulation

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; FEMALE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 72; HUMAN PAPILLOMAVIRUS TYPE 82; HUMAN PAPILLOMAVIRUS TYPE 83; INFECTION PREVENTION; NONHUMAN; NORMAL HUMAN; POLYMERASE CHAIN REACTION; PROSTITUTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TUNISIA; VIRUS DETECTION; VIRUS TYPING; WART VIRUS;

ADULT; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROSTITUTION; RISK FACTORS; TUNISIA;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; PAPILLOMAVIRIDAE;

EID: 33744960431     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20646     Document Type: Article

References (19)

1. Bernard HU, Chan SY, Manos MM, Ong CK, Villa LL, Delius H, Peyton CL, Bauer HM, Wheeler CM. 1994. Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence, and phylogenetic algorithms. J Infect Dis 170:1077-1085.
2. Clifford GM, Smith JS, Aguado T, Franceschi S. 2003. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: A meta-analysis. Br J Cancer 89:101-105.
3. Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S, Anh PT, Ferreccio C, Hieu NT, Matos E, Molano M, Rajkumar R, Ronco G, de Sanjose S, Shin HR, Sukvirach S, Thomas JO, Tunsakul S, Meijer CJ, Franceschi S, and the IARC HPV Prevalence Surveys Study Group. 2005. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: A pooled analysis. Lancet 366:991-998.
4. de Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ. 1995. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 76:1057-1062.
5. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. 2004. Classification of papillomaviruses. Virology 324:17-27.
6. Franco EL, Harper DM. 2005. Vaccination against human papillomavirus infection: A new paradigm in cervical cancer control. Vaccine 23:2388-2394.
7. Hammouda D, Munoz N, Herrero R, Arslan A, Bouhadef A, Oublil M, Djedeat B, Fontaniere B, Snijders P, Meijer C, Franceschi S. 2005. Cervical carcinoma in Algiers, Algeria: Human papillomavirus and lifestyle risk factors. Int J Cancer 113:483-489.
8. Hassen E, Chaieb A, Letaief M, Khairi H, Zakhama A, Remadi S, Chouchane L. 2003. Cervical human papillomavirus infection in Tunisian women. Infection 31:143-148.
9. Huang S, Afonina I, Miller BA, Beckmann AM. 1997. Human papillomavirus types 52 and 58 are prevalent in cervical cancers from Chinese women. Int J Cancer 70:408-411.
10. Hwang T. 1999. Detection and typing of human papillomavirus DNA by PCR using consensus primers in various cervical lesions of Korean women. J Korean Med Sci 14:593-599.
11. Lalaoui K, El Mzibri M, Amrani M, Belabbas MA, Lazo PA. 2003. Human papillomavirus DNA in cervical lesions from Morocco and its implications for cancer control. Clin Microbiol Infect 9:144-148.
12. Manos MM, Ting Y, Wright DK, Lewis AJ, Broker TR, Wolinsky SM. 1989. Use of the polymerase chain reaction amplification for the detection of genital human papillomavirus. In Fruth M, Greaves M, editors. Cancer Cells, Vol 7: Molecular diagnostics of human cancer. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press: 209-214.
13. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meier CJ, for the International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518-527.
14. Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D, Shah KV, Meijer CJ. 2004. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111:278-285.
15. Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erlich HA. 1988. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 239:487-491.
16. Taira AV, Neukermans CP, Sanders GD. 2004. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 10:1915-1923.
17. Tjalma WA, Arbyn M, Paavonen J, van Waes TR, Bogers JJ. 2004. Prophylactic human papillomavirus vaccines: The beginning of the end of cervical cancer. Int J Gynecol Cancer 14:751-761.
18. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12-19.
19. zur Hausen H, de Villiers EM. 1994. Human Papillomaviruses. Annu Rev Microbiol 48:4274-47.